New data from BMJ Global Health presents a stark picture of healthcare disparities: 300 million people across Africa carry the sickle cell trait, yet less than 1% of eligible patients receive advanced treatments. The burden is concentrated in sub-Saharan regions, with West Africa accounting for 25% of cases, Central Africa 20%, and East Africa 15%.
This substantial treatment gap reflects systemic infrastructure deficits rather than lack of therapeutic options. Emerging gene therapies and cellular treatments represent genuine opportunities for disease transformation, but their deployment requires specialized laboratory infrastructure, trained personnel, and sophisticated cold chain logistics—capabilities currently absent across most African healthcare facilities.
The disparity between disease prevalence and treatment availability highlights the critical need for targeted infrastructure investment. Without coordinated development of laboratory accreditation programs and workforce training initiatives, millions will continue lacking access to life-saving therapies that could fundamentally alter disease outcomes.
Read the full article on GMJ Newsroom.
Was this article helpful?
